TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT03708900: Pharmacokinetic (PK), Pharmacodynamic (PD) and Tolerability of Osilodrostat in Pediatric Patients With Cushing's Syndrome

Sponsor: RECORDATI GROUP · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$1,826,000

Rescue Site Savings

+$1,195,200

Unlock Full NCT03708900 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03708900 Rescue Dossier →